Attruby, a near-complete TTR stabilizer, is the first FDA-approved treatment for ATTR-CM, reducing cardiovascular death and hospitalizations. It demonstrated rapid benefits, with a 42% reduction in composite ACM and recurrent CVH events, and a 50% reduction in CVH events at Month 30. BridgeBio will provide Attruby free for life to U.S. clinical trial participants and offers extensive access programs. The company will receive a $500 million payment under its royalty funding agreement and plans global approvals, starting with Europe in 2025.